Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 009

Next Previous
Drug Profile

CTX 009

Alternative Names: ABL-001; ABL001 - ABL Bio; CTX-009; ES 104; HD-B001A; NOV1501; TR-009

Latest Information Update: 15 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ABL Bio
  • Developer ABL Bio; Compass Therapeutics; Elpiscience Biopharmaceuticals; National OncoVenture
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Biliary cancer
  • Phase II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumors released by Compass Therapeutics
  • 10 May 2023 Compass Therapeutics has patent protection for DLL4/VEGF antibody program including CTX 009 in USA and foreign jurisdictions
  • 10 May 2023 Compass Therapeutics plans clinical trials for Biliary tract cancer, Colorectal cancer, and Ovarian cancer in USA (Compass Therapeutics pipeline, May 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top